Genome sequencing. The guy who runs it used to be with 23 and Me.
Softbank (!) and Fidelity invested.
CNBC: “10X Genomics Inc. 10X Genomics, Inc. is a United States-based company that offers products that deliver genomic data. The Company’s solutions include Gene Expression Profiling, Gene Expression CRISPR Screening, Immune Profiling, Immune Profiling and Cell Surface Protein, Immune Profiling and Antigen Specificity, Chromatin Accessibility, Spatial Gene Expression Profiling and Copy Number Variation.”
Biotech start-up 10x Genomics surged as much as 49% in its market debut Thursday. The stock opened trading at $54 and rose as high as $58 per share midday before closing at $53.
The company, which provides scientists gene sequencing technologies to help cure chronic diseases like cancer and Alzheimer’s, priced its 9 million shares Wednesday night at $39 per share, above the expected range of $31 and $35.
The stock is among the top 25 IPO debut performances year to date.
10x Genomics is backed by investors like Softbank, Fidelity and Meritech Capital partners, among others.